Purpose: Boron neutron capture therapy (BNCT) is an emerging binary radiotherapy, which is limited for application due to the challenge of targeted delivery into tumor nowadays. Here, we propose the use of iRGD-modified polymeric nanoparticles for active targeted delivery of boron and doxorubicin (DOX) in BNCT.
Methods: B-10-enriched BSH was covalently grafted to PEG-PCCL to prepare B-10-polymer, then surface-modified with iRGD. And, DOX was physically incorporated into polymers afterwards. Characterization of prepared polymers and in vitro release profile of DOX from polymers were determined by several methods. Cellular uptake of DOX was observed by confocal microscope. Accumulation of boron in cells and tissues was analyzed by ICP-MS. Biodistribution of DOX was studied by ex vivo fluorescence imaging and quantitative measurement. Tumor vascular normalization of Endostar for promoting delivery efficiency of boron on refractory B16F10 tumor was also studied.
Results: The polymers were monodisperse and spheroidal in water with an average diameter of 24.97 nm, which were relatively stable at physiological pH and showed a sustained release of DOX, especially at endolysosomal pH. Enhanced cellular delivery of DOX was found in iRGD-modified polymer group. Cellular boron uptake of iRGD-modified polymers in A549 cells was remarkably raised fivefold (209.83 ng B-10/10(6) cells) compared with BSH. The polymers represented prolonged blood circulation, enhanced tumor accumulation of B-10 against BSH, and favorable tumor:normal tissue boron concentration ratios (tumor:blood = 14.11, tumor:muscle = 19.49) in A549 tumor-bearing mice 24 hrs after injection. Both fluorescence imaging and quantitative measurement showed the highest tumor accumulation of DOX at 24 hrs after injecting of iRGD-modified polymers. Improvement of vascular integrity and reduction of vascular mimicries were found after Endostar injection, and raised tumor accumulation of boron as well.
Conclusion: The developed nanoparticle is an inspiring candidate for the safe clinical application for BNCT.
[1]Zhejiang Univ, Key Lab Canc Prevent & Intervent, Affiliated Hosp 2, Dept Radiat Oncol,Minist Educ,Coll Med, Hangzhou 310009, Zhejiang, Peoples R China.
[2]Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmaceut, Hangzhou 310058, Zhejiang, Peoples R China.
[3]Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol TCM, Shanghai 201203, Peoples R China.
[4]Fujian Med Univ, Affiliated Hosp 1, Dept Spinal Surg, Fuzhou 350005, Fujian, Peoples R China.
(8.0+极速模式)